The US Food and Drug Administration (FDA) is investigating the deaths of 2 patients that occurred within days of their receiving intramuscular injections of the antipsychotic medication olanzapine pamoate (http://1.usa.gov/1at8C7E).
The FDA is warning clinicians about reports of these deaths, which occurred 3 to 4 days after an olanzapine pamoate injection. Although the patients received doses the FDA deemed “appropriate,” blood tests after death found high levels of olanzapine. High levels of this drug may cause cardiopulmonary arrest, cardiac arrhythmias, coma, or delirium.
Kuehn BM. FDA Investigates Deaths Related to Use of Olanzapine Pamoate. JAMA. 2013;310(4):361. doi:10.1001/jama.2013.50117
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: